Leerink upgraded Amgen to Outperform from Market Perform with a price target of $318, up from $267. The analyst notes that the upgrade is both a multiple-expansion and earnings-upside call. Leerink expects the P/E multiple to expand due to accelerating pipeline newsflow – including in oncology, obesity, and cardiovascular disease – and also expects upward pressure on both near- and long-term EPS due to accretion from the acquisition of Horizon Therapeutics that closed on October 6, the analyst tells investors.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AMGN: